Study investigates the pathophysiological mechanisms of PASC after COVID-19

Researchers investigated early pathophysiological mechanisms potentially underlying PASC post-SARS-CoV-2 infection.

ASCO 2024: MediLink’s NSCLC and breast cancer ADC shows early safety success – Pharmaceutical Technology

A 3D rendering of an antibody drug conjugate (ADC). YL202/BNT326 is an ADC designed to target HER3 and inhibit topoisomerase 1. Credits: Love Employee/Shutterstock.com MediLink

May 24, 2024

FDA approves Eli Lilly’s early Alzheimer’s treatment

Eli Lilly’s early Alzheimer’s treatment was approved by the Food and Drug Administration on Tuesday, making it the second drug on the U.S. market aimed

July 2, 2024

Exclusive: Pfizer to invest $25M into tiny UK biotech with epigenetics approach to cancer

Cambridge, UK-based startup CellCentric is receiving $25 million to finish ongoing clinical studies and get some extra runway in the form of a cash infusion

July 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.